All the news Showing 10 of 248 articles from: Interferon-free regimensGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir/velpatasvir + GS-9857 works well for treatment-experienced hepatitis C patients Liz Highleyman / 15 April 2016 A triple combination of Gilead Sciences' sofosbuvir, velpatasvir and GS-9857 demonstrated a high sustained response rate for treatment-experienced people with all hepatitis C virus (HCV) genotypes who previously were not cured with prior ... Tailoring hepatitis C treatment duration to viral load responses could cut costs Keith Alcorn / 31 March 2016 Hepatitis C viral load testing during treatment can be used to predict which patients have been cured after a shorter course of treatment, potentially cutting the cost of treatment by up to ... Sofosbuvir/ledipasvir for 6 weeks cures HCV in HIV-positive people with acute HCV if viral load is low Liz Highleyman / 26 February 2016 An interferon- and ribavirin-free regimen of sofosbuvir/ledipasvir (Harvoni) taken for just 6 weeks was enough to cure hepatitis C in HIV-positive people with recent hepatitis C virus (HCV) infection if their HCV viral ... RG-101 Interim Analysis Shows 97% Response at 8 Week Follow-Up Regulus Therapeutics press release / 17 February 2016 Australia: Treatment Has Changed campaign Hepatitis New South Wales / 17 February 2016 U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease Gilead press release / 17 February 2016 MiR-122 inhibitor RG-101 suppresses hepatitis C virus with a single dose Liz Highleyman / 15 February 2016 A single injection of RG-101, an experimental drug that targets the micro-RNA miR-122 in liver cells, reduced hepatitis C virus (HCV) levels by more than 4 log10 in people with HCV genotypes 1, ... Fair Pricing Coalition Recognizes Merck’s Lower Price for Curative Hepatitis C Treatment, Calls for Manufacturers to Reduce Excessive Prices and Increase Patient Assistance Fair Pricing Coalition / 08 February 2016 Merck Throws a Wrench in Drug Pricing Bloomberg / 01 February 2016 Zepatier for hepatitis C approved in Canada CATIE / 01 February 2016 ← Prev1...23456...25Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive